You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Renal cancer

Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

  • Technology appraisal guidance
  • Reference number: TA333
  • Published:  25 February 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Research recommendations coming out of this guidance

  • NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

Back to top